ESMO25

Myriam Chalabi: Long awaited practice-changing results from phase 3 CM8HW are out

Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher in Gastrointestinal Oncology at Antoni van Leeuwenhoek, The Netherlands Cancer Institute (NKI), recently shared an article she and her colleagues authored on X:

“Long awaited practice-changing results from ph 3 CM8HW now out in The Lancet. Nivo/ipi sign better than nivo mono in dMMR mCRC.”

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Authors: Thierry André et al.

Myriam Chalabi: Long awaited practice-changing results from phase 3 CM8HW are out

cancer Metastatic colorectal cancer Myriam Chalabi Nivolumab plus ipilimumab OncoDaily Oncology